Related Experiment Video
Updated: May 1, 2026

06:54
Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion
Published on: June 15, 2019
5.3K
Molecular Interactions between Complement Factor H and Its Heparin and Heparan Sulfate Ligands
Stephen J Perkins1, Ka Wai Fung1, Sanaullah Khan1
1Department of Structural and Molecular Biology, University College London , London , UK.
Frontiers in Immunology
|April 19, 2014
Summary
Complement factor H (CFH) regulates complement protein C3b. Understanding CFH
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Complement factor H (CFH) is crucial for regulating the alternative complement pathway.
- Heparan sulfate (HS) on cell surfaces plays a role in CFH-mediated complement regulation.
- Understanding the molecular interactions of CFH with HS is key to elucidating complement activation mechanisms.
Purpose of the Study:
- To determine the solution structures of heparin and desulfated HS.
- To characterize the binding interaction between CFH and HS.
- To propose a molecular model for CFH binding to cell surfaces.
Main Methods:
- Solution structural studies using scattering and ultracentrifugation.
- Analysis of HS and heparin oligosaccharide structures.
- Determination of CFH domain structure.
- Binding studies using CFH fragments and heparin-coated sensor chips.
Main Results:
- HS and heparin exhibit distinct solution structures with varying flexibility.
- CFH binds preferentially to the sulfated S-regions of HS over NA-regions.
- A two-site, co-operative binding model for CFH interaction with cell surface HS was identified.
- Moderate binding affinities (micromolar dissociation constants) were observed for CFH-heparin and CFH-C3b interactions.
Conclusions:
- CFH interacts with cell surface HS via a two-site mechanism, influencing its interaction with C3b.
- Defects in either CFH-heparin binding site can impair complement regulation and lead to immune disorders.
- This study provides molecular insights into the role of CFH-HS interactions in maintaining immune homeostasis.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Complement System
10.6K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
10.6K
Extrinsic and Intrinsic Pathways of Hemostasis
10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
Factors Affecting Protein-Drug Binding: Drug Interactions
727
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
727
Fibril-associated Collagen
2.7K
Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
2.7K
Drug Binding to Blood Components
666
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
666

